Manuel de Jesus Diaz Verduzco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Manuel de Jesus Diaz Verduzco has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Adalberto Sperb Rubin
Santa Casa Hospital Porto Alegre/UFCSPA, Brazil
1 shared publication Alexandre Amaral
División de neumología, Instituto de Curazao (InCor), Hospital de Clínicas, Universidad de san Pablo, San Pablo, Brazil
1 shared publicationAlfredo Pachas
Centro de Enfermedades Respiratorias Neumología Peruana, Lima, Peru
1 shared publicationAlvaro Undurraga
Instituto Nacional del Tórax, Santiago, Chile
1 shared publicationAníbal Bermúdez
Hospital Italiano de Córdoba, Córdoba, Argentina
1 shared publicationBrenda Varela
Hospital Alemán, Buenos Aires, Argentina
1 shared publication
Latest Publications
- Open Access
- 19 May 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (5) , 647
Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America
Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study was conducted in reference centers for interstitial lung diseases in Brazil and Mexico with a panel of four specialists. The patient’s journey in both countries begins when the patient seeks medical care after observing a chronic respiratory symptom. In both countries, due to diagnostic complexity, these patients arrive at ILD referral centers at an advanced stage of the disease. Once diagnosis is established, the treatment onset differs between Mexico and Brazil. In Brazil, access to antifibrotic drugs through the public health system has been a significant challenge, and their cost makes them unaffordable for most people. This situation forces medical specialists to provide only supportive care to patients until these drugs can be accessed. In Mexico, antifibrotics have been available in health sectors since 2018. Brazil and Mexico have several similarities regarding the initial journey of the patient due to diagnosis difficulties. Still, the outcome tends to be different due to a difference in access to treatment with antifibrotics. For this reason, advancing health policies that ensure proper treatment for patients with ILD is crucial for the sustainability and reliability of the health system.
- 19 May 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (5) , 647
Open AccessImproving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America
Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study was conducted in reference centers for interstitial lung diseases in Brazil and Mexico with a panel of four specialists. The patient’s journey in both countries begins when the patient seeks medical care after observing a chronic respiratory symptom. In both countries, due to diagnostic complexity, these patients arrive at ILD referral centers at an advanced stage of the disease. Once diagnosis is established, the treatment onset differs between Mexico and Brazil. In Brazil, access to antifibrotic drugs through the public health system has been a significant challenge, and their cost makes them unaffordable for most people. This situation forces medical specialists to provide only supportive care to patients until these drugs can be accessed. In Mexico, antifibrotics have been available in health sectors since 2018. Brazil and Mexico have several similarities regarding the initial journey of the patient due to diagnosis difficulties. Still, the outcome tends to be different due to a difference in access to treatment with antifibrotics. For this reason, advancing health policies that ensure proper treatment for patients with ILD is crucial for the sustainability and reliability of the health system.
- 4 June 2022
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 58 (12) , 794-801
Latin American Registry of Idiopathic Pulmonary Fibrosis (REFIPI): Clinical Characteristics, Evolution and Treatment
- 4 June 2022
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 58 (12) , 794-801
Latin American Registry of Idiopathic Pulmonary Fibrosis (REFIPI): Clinical Characteristics, Evolution and Treatment
- 25 February 2006
- Vol. 44 (1) , 35-8
[Community-acquired pneumonia: risk focus and family functionality].
Community-acquired pneumonia is one of the five most prevalent causes of death worldwide; in Mexico, it accounts for more than 10% of the hospital admissions. To identify the risk factors and the kind of family functionality associated to community-acquired pneumonia among adult patients. With the prior authorization of the research and bioethics committees, a study of cases and controls took place, where both groups were asked about the following variables: alcohol consumption or active smoking, conditions of house and family functionality, anti-flu and anti-pneumococcal vaccination, disablement, and chronic pulmonary disease, among others. It was found that the significant variables were active smoking, disablement, pulmonary emphysema, chronic bronchitis, overcrowding at home, and alcohol consumption; and with a protective effect for this disease: a functional family and anti-pneumococcal vaccination. There are risk factors that predispose the development of community-acquired pneumonia, and that allow us to make a population profile in which some preventive strategy could diminish the frequency and lethality of this disease.
- 25 February 2006
- Vol. 44 (1) , 35-8
[Community-acquired pneumonia: risk focus and family functionality].
Community-acquired pneumonia is one of the five most prevalent causes of death worldwide; in Mexico, it accounts for more than 10% of the hospital admissions. To identify the risk factors and the kind of family functionality associated to community-acquired pneumonia among adult patients. With the prior authorization of the research and bioethics committees, a study of cases and controls took place, where both groups were asked about the following variables: alcohol consumption or active smoking, conditions of house and family functionality, anti-flu and anti-pneumococcal vaccination, disablement, and chronic pulmonary disease, among others. It was found that the significant variables were active smoking, disablement, pulmonary emphysema, chronic bronchitis, overcrowding at home, and alcohol consumption; and with a protective effect for this disease: a functional family and anti-pneumococcal vaccination. There are risk factors that predispose the development of community-acquired pneumonia, and that allow us to make a population profile in which some preventive strategy could diminish the frequency and lethality of this disease.